Predictive Value of SVR4 With Glecaprevir/Pibrentasvir in Patients With Cirrhosis, HCV-HIV Coinfection, Recent Injection Drug Use, or Acute Infection

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Predictive Value of SVR4 With Glecaprevir/Pibrentasvir in Patients With Cirrhosis, HCV-HIV Coinfection, Recent Injection Drug Use, or Acute Infection

	AASLD 2026 Denver